Your browser doesn't support javascript.
loading
Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research.
Cardillo, Anthony B; Kovar, Sierra; Roper, Nitin; Hicks, David G; Velez, Moises J.
Afiliación
  • Cardillo AB; Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
  • Kovar S; Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
  • Roper N; Developmental Therapeutic Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD.
  • Hicks DG; Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
  • Velez MJ; Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
Ann Med Surg (Lond) ; 85(6): 2640-2646, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37363568
ERBB2 (HER2) is a gene in humans that encodes the ERBB2 protein, a member of the epidermal growth factor receptor family. Non-small cell lung carcinomas do not commonly harbour ERBB2 mutations, with clinical trials conducted to assess for targeted response and progression-free survival. We retrieved cases of lung adenocarcinoma with next-generation sequencing proven ERBB2 point mutations (n=8) or amplifications (n=11) and assessed the concordance of commercially available ERBB2 (HER2) immunohistochemical antibodies with the next-generation sequencing result. At present, no commercially available ERBB2 clone can accurately detect ERBB2 mutations consistently in non-small cell lung carcinoma specimens, but amplifications can be detected with reasonable diagnostic accuracy.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Ann Med Surg (Lond) Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Ann Med Surg (Lond) Año: 2023 Tipo del documento: Article